The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice
- PMID: 16778075
- PMCID: PMC1482477
- DOI: 10.1101/gad.1395006
The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice
Abstract
The tumor suppressor PTEN is frequently inactivated in human cancers. A major downstream effector of PTEN is Akt, which is hyperactivated via PTEN inactivation. It is not known, however, whether diminished Akt activity is sufficient to inhibit tumorigenesis initiated by Pten deficiency. Here we showed that the deficiency of Akt1 is sufficient to dramatically inhibit tumor development in Pten+/- mice. Akt1 deficiency had a profound effect on endometrium and prostate neoplasia, two types of human cancer, in which PTEN is frequently mutated, and also affected thyroid and adrenal medulla tumors and intestinal polyps. Even haplodeficiency of Akt1 was sufficient to markedly attenuate the development of high-grade prostate intraepithelial neoplasia (PIN) and endometrial carcinoma. These results have significant implications for cancer therapy.
Figures
References
-
- Brazil D.P., Hemmings B.A. Ten years of protein kinase B signalling: A hard Akt to follow. Trends Biochem. Sci. 2001;26:657–664. - PubMed
-
- Cantley L.C. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–1657. - PubMed
-
- Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004;10:33–39. - PubMed
-
- DeFeo-Jones D., Barnett S.F., Fu S., Hancock P.J., Haskell K.M., Leander K.R., McAvoy E., Robinson R.G., Duggan M.E., Lindsley C.W., et al. Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific Akt/PKB family members. Mol. Cancer Ther. 2005;4:271–279. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous